Company Encyclopedia
View More
name
OS Therapies
OSTX.US
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
1.925 T
OSTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning

    Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated with a price target of $6.00. The positive Type C meeting with the FDA supports potential accelerated approval for their osteosarcoma treatment. The OST-HER2 program holds multiple FDA designations, enhancing its review potential. The company plans to release biomarker data at the JPM Healthcare Conference. Lake Street also maintained a Buy rating with a $17.00 price target.

    Tip Ranks·
    US
    OSTX
    -1.99%
    Tip Ranks·
    US
    OSTX
    -1.99%

    Lake Street Sticks to Their Buy Rating for OS Therapies Incorporated (OSTX)

    Lake Street analyst Chad Messer maintains a Buy rating for OS Therapies Incorporated, setting a price target of $17.00. The analyst has an average return of -0.6% and a 37.09% success rate. OS Therapies has a Moderate Buy consensus with a price target of $11.50.

    Tip Ranks·
    US
    OSTX
    -1.99%
    Tip Ranks·
    US
    OSTX
    -1.99%

    OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | OSTX Stock News

    OS Therapies held a successful Type C meeting with the FDA regarding the Phase 2b trial of OST-HER2 for osteosarcoma. FDA confirmed that single-arm study data could support a BLA under the Accelerated Approval Program. A confirmatory study design was proposed, and canine data may support human clinical benefit. The company plans to submit BLA documents by January 2026 and release biomarker analysis data during the JP Morgan Healthcare Conference in January 2026.

    StockTitan·
    US
    OSTX
    -1.99%
    StockTitan·
    US
    OSTX
    -1.99%

    OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation

    OS Therapies Inc. has unveiled its cancer immunotherapy pipeline, highlighting the OST-HER2 program targeting osteosarcoma, with potential applications in breast cancer and other tumors. The company aims for accelerated approval by 2026 and projects a Priority Review Voucher sale of $160 million. The pipeline includes candidates for various cancers, with a market cap of $60 million and cash holdings of $4 million.

    Reuters·
    US
    OSTX
    -1.99%
    Reuters·
    US
    OSTX
    -1.99%

    OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

    OS Therapies announced a successful pre-Marketing Authorisation Application meeting with the UK MHRA for its Phase 2b clinical trial of OST-HER2, aimed at preventing recurrent pulmonary metastatic osteosarcoma. The company achieved alignment on key points and plans to submit a conditional MAA by January 2026. Feedback from the UK MHRA will aid preparations for a US FDA meeting. OST-HER2 has received various designations and positive trial data, with a BLA submission anticipated in Q1 2026.

    Newsfile Corp.·
    US
    OSTX
    -1.99%
    Newsfile Corp.·
    US
    OSTX
    -1.99%
    © 2025 Longbridge｜Disclaimer